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Abstract 
BACKGROUND: Post-surgical recurrence of cancer colon occurs in one-third of patients within the first two 
years, so early detection is important. The assessment of the therapeutic response is important to change 
protocol strategy. Positron emission tomography/computed tomography PET/CT, a valuable tool gives both 
metabolic and anatomic information for whole-body regions. Obesity is an important risk factor for colorectal 
cancer. 
AIM: To evaluate post-surgical and therapeutic colorectal cancer by PET/CT and study obesity association to its 
prognosis. 
METHODS: This was a prospective study involved 93 patients with, post-surgical colorectal cancer examined by 
PET/CT, then follow up after 4-6 months.  
RESULTS: There was a statistically significant difference between PET/CT and contrast CT. The sensitivity& the 
specificity were (96.4%-100% & 92.3%-98.2%) for PET/CT and (84.2%-90.2% & 76.5%-85.4%) for contrast CT 
respectively. Post-therapeutic follow up showed; progressive course (24.5%), stationary course (26.4%), partial 
regression (28.3%) and complete regression course (20.8%). Obesity is a risk factor for progression with highly 
statistically significant to treatment response. Obese patients had a progressive or stationary course of the 
disease. Also, there was a highly statistically significant association between total abdominal fat & visceral 
abdominal fat areas with good response of treatment. 
CONCLUSION: PET/CT is the most appropriate imaging technique to detect any recurrence or metastases in 
post-surgical colorectal cancer with high sensitivity and specificity comparing to CT. Obesity is a predictor risk 
factor for prognosis of the disease, as generally and abdominally (total & visceral fat) had an association with 
therapeutic response. 
 
 
 
 
Introduction 
 
Worldwide more than one million people get 
colorectal cancer yearly [1]. Also, it is the third most 
commonly diagnosed cancer in males and the second 
in females, with 1.8 million new cases and almost 
861,000 deaths in 2018, according to GLOBOCAN 
database. The highest incidence rates are in Europe, 
North America, Australia, and New Zealand, while the 
lowest rates are in South-Central Asia and Africa
 
[2]. 
Colorectal cancer is the 7th commonest cancer in 
Egypt; it represents 3.5% of male cancers and 3% of 
female cancers [3]. The estimated numbers of colon 
cancer patients were more than three thousand in 
2015 [3]. 
Post-surgical recurrence of cancer colon 
occurs within the first two years. It can recur loco-
regionally or at distant sites [4]. In therapy, resection 
of one metastasis is associated with good survival 
rate while multifocal metastatic lesions give a less 
favourable prognosis [5]. Also, the assessment of the 
therapeutic response (chemo-radiotherapy) is 
important for change protocol strategy of ineffective 
and toxic chemotherapy [6]. So, early detection helps 
design the clinical therapeutic guidelines; secondary 
operation, radiotherapy or chemotherapy.  
Serum carcinoembryonic antigen (CEA) and 
contrast computed tomography (CT) are conventional 
methods. As serum CEA levels are used for 
recurrence monitoring, with its high-level imaging 
modality will be necessary to localise the site of 
recurrence and metastases [7].
 
Regarding changes of 
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anatomical structures and fibrous tissue in the 
operative region, contrast CT is likely unable to 
differentiate postsurgical changes from recurrence 
and may miss metastatic deposits. While the 
functional imaging; Fluorine-18 fluoro-D-glucose 
positron emission tomography / computed 
tomography (18F-FDG PET/CT) scan can be greatly 
used to recognise the metabolic characteristics of the 
lesions and detect any active cells [8]. The integrated 
PET/CT gives both metabolic and anatomic 
information with a single device at one diagnostic 
session for the whole-body regions to detect any 
recurrence and metastases [9]. 
Several studies reported that obesity is an 
important risk factor for colorectal cancer [10], [11], 
[12], [13], while Scarpa et al., showed the role of 
obesity in postoperative recurrence and multifocal 
disease [14]. 
The aims of this study; to evaluate post-
surgical and therapeutic colorectal cancer by PET/CT 
for proper management, also predict the effect of 
obesity as a risk factor in prognosis among a sample 
of Egyptian patients. 
 
Sample size estimation 
The sample size was calculated using PASS 
11 (USA), regarding the proportional of PET/CT 
sensitivity at the previous study; 90 subjects were 
adequate with power 90.0%, α = 0.05, and B = 0.1  
 
 
Patients and Methods 
 
Design: A prospective study 
Ethics: This study was approved by the 
research ethics committee, faculty of medicine, 
Helwan University (FMHU 1-2019) and informed 
written consent were signed by each patient. 
Participants: Ninety-four Egyptian’s patients 
with post-surgical cancer colon, examined for follow 
up after 4-6 months by PET/CT, both genders were 
included in this study (55 males and 39 females); their 
ages were ranged from 38 to 75 years. They were 
referred from clinical oncology and surgery 
departments due to elevated CEA or follow up to 
assess the effect of treatment. The inclusion criteria: 
pathologically proven colorectal carcinoma and 
underwent appropriate therapy for 4-6 months. 
Exclusion criteria included those who had a bad 
general condition, impaired renal function, allergy to 
intravenous contrast material and a blood glucose 
level > 200 mg/dl at the time of the study. 
The duration of the study: January 2019- June 
2019. 
Location: Misr Radiology center (MRC), Cairo, 
Egypt. 
 
 
Methods 
 
Patient preparation: allow low carbohydrate 
and high protein diets with liquids (24 hours before), 
then fasting 6 hours before the examination. 
The day of examination: complete history was 
taken and indication (High tumour marker CEA and 
previous PET/CT scan for follow up), then 
measurements were taken before starting the 
examination: Fasting blood sugar, body height and 
weight (using a Seca scale balance and 
anthropometer with light clothes and no shoes, the 
measure was taken to nearest 0.1 cm and 0.01 kg 
respectively) [15]. The Body mass index (BMI) was 
calculated as; the weight (kg)/ height (m
2
) and 
classified into; (18.5 ≥ normal weight < 25), (≥ 25 
overweight < 30) and obese (≥ 30)
 
[16]. 
Examinations: Intravenous injection of 5 – 10 
mCi as an average dose of 
18
F-FDG (0.1 mCi/Kg) one 
hour before starting the scan. Each patient was 
examined by PET/CT using Phillips Ingenuity TF, 128 
slice machines (Cleveland, OH, USA) as the following 
A low-dose non-contrast CT for attenuation correction 
followed by PET scan from the skull to the mid-thigh, 
then a diagnostic post-contrast CT using nonionic 
contrast medium. Those PET images were assessed 
by both visually & semi-quantitatively for the regions 
with pathologic tracer accumulation using maximum 
standardized uptake value (SUVmax); loco-regional 
lesion (recurrent) was identified by presence of 
metabolically active tumour tissue with high FDG 
accumulation and correlated this activity to its 
anatomical site in the combined PET/CT images, the 
lymph nodes and distant metastases (lung, liver, 
bone, brain, and others) were evaluated as well. The 
comparison between the recent scan and the previous 
one in follow up cases was made to evaluate the 
response of treatment (Fig. 1). 
The assessment of therapeutic response 
evaluated by PET/CT according to RECIST criteria 
[17]: 
- Complete response (CR): The 
disappearance of FDG uptake at the target tumour 
lesion.no new FDG avid lesion. 
- Partial response (PR): reduction at least a 
30% in target measurable tumour FDG uptake, taking 
the baseline lesion as a reference. 
- Progressive disease (PD): at least a 25% 
increase in tumour SUVmax peak uptake, taking a 
reference the baseline lesion from starting of 
treatment or an appearance of a new lesion or more. 
- Stationary disease (SD): no sufficient 
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changes, almost same as reference baseline lesion 
from starting of treatment; less than 25% increase (not 
PD) and 30% decrease (not PR). No new lesion. 
Regarding abdominal fat assessment, no 
extra-scan was required, the analysis was processed 
by special software at an advanced workstation (AW 
Volumeshare2- version 4.4 Software), assessed total, 
visceral and subcutaneous abdominal fat 
compartments at the L4-L5 level by drawing then a 
calculation of area was done.  
 
Statistical Analysis 
SPSS version 22 software was used to 
analyse the data; mean ± standard deviations (SD) for 
parametric data, numbers (percentage) for the 
frequency distribution of non-parametric data, 
crosstabs for sensitivity and specificity, Chi-square, 
Pearson´s correlation test, and odds ratio. A 
significance was set at P = 0.05  
 
 
Results 
 
This study included 94 patients: 55 male 
(58.5%) and 39 female (41.5%), their age ranged from 
38 to 75 years (mean ± SD: 58.3 ± 4.1 years), weight; 
61-109 kg (90.9 ± 5.8 kg), height; 153-169 cm (162.8 
± 3.7 cm), BMI; 22.6-39.8 kg/m2 (34.4 ± 5.4 kg/m2) 
and fasting blood sugar; 70-197 mg/dl (101.2 ± 2.4 
mg/dl). Regarding BMI; 31 (33%) were of normal 
weight (20 males and 11 females), 12 (12.8 %) were 
overweight (7 males and 5 females) and 51 (54.3%) 
were obese (28 males and 23 females), then 
classified into two groups; the first one included 
normal weight patients and the second one included 
both; overweight & obese to involve 63 patients 
(67%)(35 males and 28 females).  
Regarding indications; 41 patients underwent 
PET-CT post-surgical, while 53 patients follow up 
post-therapeutic (chemo and radiotherapy) to assess 
the response of treatment, as well, 62 patients (66%) 
had elevated tumour marker CEA, and 32 had a 
negative marker (34%). The CEA was (0.9-116 
ng/ml). 
The frequency distribution of local recurrence 
lesions and metastatic deposits detected by contrast 
CT and PET/CT imaging for a total of 94 patients 
(Table 1), revealed; lymph nodes metastasis were the 
most frequent site (36.2% and 46.8%) for CT and 
PET/CT respectively followed by local recurrence & 
hepatic deposits (25.5%) by CT, while local 
recurrence represents (34%) by PET/CT then 
peritoneal deposits (18.1% and 28.7%), pulmonary 
deposits (14.9% and 17%) and osseous deposits 
(11.7% and 23.4%) by CT and PET/CT respectively. 
Although PET/CT gives additional information about 
active tumour cell by measuring its avidity to 
18
F-FDG 
uptake and measuring the maximum standardised 
uptake values (SUVmax). Its ranges were; 9-29.4 
(mean 17.2 ± 5.4 SD) for local recurrence, 4.5-29.7 
(mean 13.3 ± 6.9 SD) for LN metastasis, 5.7-23 
(mean 10.7 ± 5.2SD) for hepatic deposits, 7.7-15.3 
(mean 11.9 ± 2.5SD) for peritoneal deposits, 7.7-15.3 
(mean 10.8 ± 6.1SD) for pulmonary deposits and 4.5-
11.8 (mean 9.1 ± 1.7SD) for osseous deposits. 
Table 1: Frequency distribution of local recurrence and 
metastatic lesions detected by Contrast CT and PET/CT 
 Contrast CT PET/CT p-value 
No. &frequency No. &frequency SUVmax value 
Mean  SD 
Local Recurrence 24 (25.5%) 32 (34%) 17.2  5.4 0.000 
LN Metastasis 34 (36.2%) 44 (46.8%) 13.3  6.9 0.000 
Peritoneal Deposits 17 (18.1%) 27 (28.7%) 11.9  2.5 0.000 
Pulmonary Deposits 14 (14.9%) 16 (17%) 10.8  6.1 0.000 
Hepatic Deposits 24 (25.5%) 24 (25.5%) 10.7  5.2 0.000 
Osseous Deposits 11 (11.7%) 22 (23.4%) 9.1  1.7 0.000 
 
There were statistically significant differences 
between contrast CT and PET/CT  
(P = 0.000); 8 cases of local recurrence were missed 
by CT and detected by PET/CT, 10 cases of 
metastatic LNs and peritoneal deposits detected only 
PET/CT may be due smaller in size to localize by CT, 
as well extra 11 osseous lesions were detected by 
PET/CT (bone marrow affection) compared to CT, 
while two pulmonary nodules couldn’t be detected by 
CT as it surrounded by consolidation area and pleural 
effusion.  
Then, the sensitivity and the specificity of 
PET/CT was done related to elevated tumour 
markers, measuring (96.4%-100% & 92.3%-98.2% 
respectively) compared to contrast CT (84.2%-90.2% 
& 76.5%-85.4% respectively), the positive and 
negative predictive values were 94% and 84% for 
PET/CT, and 81% and 76.3% for CT. 
Regarding obesity, all patients were classified 
according to BMI categories; normal weight and 
(overweight & obese) with PET/CT findings to detect 
frequency of local recurrence and metastatic deposits 
on each group (Table 2), There was an insignificantly 
statistical association between obesity and PET/CT 
findings (no significant differences regarding sex), 
however, the most frequent local recurrence and 
metastatic deposits were detected at obese patients 
(71.9%-81.2%). 
Table 2: Comparison between BMI categories (normal weight 
and overweight &obese) with PET/CT findings 
PET/CT Normal Weight 
No.&% 
Overweight & Obese 
No.&% 
p-value 
Local Recurrence 9 (28.1%) 23 (71.9%) 0.312 
LN Metastasis 12 (27.3%) 32 (72.7%) 0.074 
Peritoneal Deposits 9 (33.3%) 18 (66.7%) 0.865 
Pulmonary Deposits 3 (18.8%) 13 (81.2%) 0.410 
Hepatic Deposits 5 (20.8%) 19 (79.2%) 0.314 
Osseous Deposits 6 (27.3%) 16 (72.7%) 0.786 
 
Then frequency distribution between obesity 
and response of treatment (post-therapeutic follow up) 
was done (Table 3). Fifty-three patients were 
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classified; normal weight and (overweight and obese), 
The assessment depends on the avidity of the lesion 
to 18 F-FDG uptakes, quantitative analysis by 
measuring (SUVmax) value and compared with the 
previously PET/CT scan from 4-6 months. Thirteen 
patients (24.5%) had a progressive course of the 
disease, all were obese, while good response of 
treatment was recorded at 40 patients (75.5%) as the 
following; stationary course (26.4%) (57.1% of them 
were obese), partial regression (28.3%) (60.0% of 
them were within normal weight) and complete 
regression course (20.8%) (54.5% of them were within 
normal weight). 
Table 3: Frequency distribution between obesity and response 
of treatment (Post-therapeutic follow up) 
 Total No. &Frequency Non obese 
No.&% 
Obese 
No.&% 
Progression 13 (24.5%) 0 (42.9%) 13 (100%) 
Good response to treatment: 40 20 20 
Stationary 14 (26.4%) 6 (42.9%) 8 (57.1%) 
Partial Regression 15 (28.3%) 9 (60.0%) 6 (40.0%) 
Complete Regression 11 (20.8%) 6 (54.5%) 5 (45.5%) 
 
The odds ratio was done to know the effect of 
obesity as a risk factor on the progression of cancer 
colon (Table 4). There was highly statistical 
significance with a response of treatment (p = 0.001, 
odd value > 2 and CI = 1.46-2.72), also hepatic and 
pulmonary deposits had high precision by odd value 
and 95% confidence interval (CI), followed by LN 
metastasis and local recurrence, while peritoneal and 
osseous deposits had a low association with obesity. 
Table 4: Odds ratio to predict if obesity a risk factor for the 
progression of the cancer colon  
 Odd Value 95% Confidence Interval P-Value 
Response of treatment 2.0 1.46-2.72 0.001** 
Local Recurrence 1.4 0.555- 3.56 0.472 
LN Metastasis 1.5 0.622-3.61 0.365 
Peritoneal Deposits 0.9 0.352-2.366 0.851 
Pulmonary Deposits 2.3 0.601-8.755 0.215 
Hepatic Deposits 2.1 0.703-6.341 0.177 
Osseous Deposits 1.3 0.463-3.843 0.594 
** Highly Significant at P ≤ 0.001. 
 
For more specification of obesity, the 
abdominal obesity assessed by CT and measured; 
total abdominal fat, subcutaneous fat and visceral 
abdominal fat areas (cm
2
), their range (100.4-998.7 
cm
2
), (80-789.6 cm
2
) and (16.27-267 cm
2
) 
respectively. Then a comparison between abdominal 
obesity and response of treatment (post-therapeutic 
follow up) regarding sex was made (Table 5).  
Table 5: Comparison between abdominal obesity and the 
response of treatment (Post-therapeutic follow up) regarding 
sex 
 Sex Progressive course 
No. (13) 
Good response to 
treatment No. (40) 
p-value 
Mean  SD Mean  SD 
Total abdominal fat 
(cm
2
) 
Male 837.72  60.5 618.20  25.5 0.008 
Female 834.74 10.2 463.04  24.9 0.054 
Subcutaneous 
abdominal fat (cm
2
) 
Male 412.11  36.0 349.16  44.8 0.203 
Female 203.54  53.5 334.70  45.5 0.370 
Visceral abdominal 
fat (cm
2
) 
Male 217.50  38.3 138.02  35.7 0.000 
Female 229.50  53.5 100.75  42.5 0.004 
 
It was revealed that; 31 males and 9 females 
had a good response of treatment, while 11 males 
and 2 females had progressive course after treatment. 
There was a highly statistically significant difference 
between total abdominal fat & visceral abdominal fat 
areas with good response of treatment at both sexes 
(P ≤ 0.001). However, no statistically significant 
difference was detected with a subcutaneous fat area. 
 
Figure 2: A 72-years old obese male patient, referred after resection 
of the recto-sigmoid mass and chemo-radiotherapy for follow up. 
Axial PET/CT images for two examinations; the first (a-d images) 
and the second examination (e, f, g, h images) after 4 months of 
treatment for comparison revealed; (a and e) progression of hyper-
metabolic peri-rectal soft tissue nodule achieving 13.38 SUVmax 
(6.79 SUVmax previously) (green arrow), while another lesion 
(yellow arrow image a) can’t be detected in newly one (b and f) a 
small active hypermetabolic lesion (recurrent) is seen at the distal 
sigmoid colon, achieving 9.86 SUVmax (red arrow image f) (c and 
g) Newly developed a small hyper-metabolic peritoneal nodule is 
noted achieving 5.44 SUVmax (yellow arrow image g) (d and h). 
Metabolically and morphologically progression of porta-hepatis 
lymph node, achieves 20.37 SUVmax (7.34 SUVmax previously) 
(back arrow) and newly developed active right hepatic lobe focal 
lesion is seen (segment VI) achieves 8.42 SUVmax (red arrow) 
 
 
Discussion 
 
The most serious problem of colorectal 
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cancer is a recurrence, as it represents around 10% - 
50% within 5 years after the surgery in the form of 
local or distant. So, the key to diminishing 
postoperative recurrence is early detection for fast 
proper management to improve the survive [9]. 
Postoperative monitoring was done by CEA 
serum level when elevated suspected of recurrence 
and imaging modality is necessary to detect any 
metastasis [18]. Contrast CT could be detected only 
sizable morphological changes, however, its inability 
to discriminate inflammatory lesions from recurrence 
or metastases [7], while 
18
F-FDG PET/CT shows early 
metabolic changes to detect any recurrence or 
metastases for choosing an adequate plan of therapy 
[8].  
Several studies and meta-analysis studies 
reported a strong positive association between obesity 
and colorectal cancer. It estimated 30%-50% of new 
diagnosed colorectal cancer cases [14, [19], [20], [21]. 
Also, obesity had an effective role in recurrence and 
prognosis of treatment, as those patients were obese 
had a higher incidence of recurrence than those had 
normal or over-weight [13]. Obesity was assessed by 
BMI, while abdominal obesity was evaluated by CT 
scan cut at L4 – L5 level [22]. 
In this Egyptian study, the first purpose was 
evaluating the role of PET/CT in post-surgical cancer 
colon comparing to contrast CT, revealed that 
sensitivity of CT was 84.2%-90.2% and for PET/CT 
was 96.4%-100%, whereas the specificity of CT was 
76.5%-85.4% and for PET/CT was 92.3%-98.2%. 
These were in agreement with the previous studies; 
that had approved PET/CT was the technique of 
choice for postoperative assessment of colorectal 
cancer to detect recurrence with sensitivity (93%-
100%) and specificity (74%-96%) [5], [6]. While, 
Stuckle et al., reported the sensitivity of CT was 38% 
– 82% in the detection of the recurrence [23]. 
In this study, more lesions were detected by 
PET/CT compared to CT, in spite of the same number 
of hepatic and almost pulmonary deposits were found 
in both imaging modalities. This, in agreement with 
Choi et al. as well had added abdominal LN [24]. 
Additionally, lymph nodes were the most 
frequent site of recurrence (46.8%) in the current 
study by PET/CT, followed by local recurrence (34%), 
peritoneal deposits (28.7%), hepatic deposits (25.5%), 
osseous deposits (23.4%) and pulmonary deposits 
(17%). 
Many studies reported that lymph nodes were 
the most frequent site of recurrence [25], [26]. 
However, Owen et al. found the liver metastasis was 
the most frequent site (50%) [27] and Chiewvit et al., 
reported, the pulmonary metastatic was the second 
site [28]. Regarding osseous lesions more lesions 
detected by PET/CT due to bone marrow affection, 
this is by Bar-Shalom et al., study, as no 
corresponding CT findings (osteolytic lesions or 
destruction of bone) at the same detected site by 
PET/CT [29].  
The second purpose of this research was to 
assess the association between obesity and colorectal 
cancer recurrence. Our findings revealed that the 
most frequent local recurrence and metastatic 
deposits were detected at obese patients (71.9%-
81.2%). Several studies concluded the association 
between obesity and colorectal cancer, as well obese 
patients had higher recurrence and mortality rates 
than normal and overweight patients [14], [30], [31], 
[32], the incidence of obese patients had colorectal 
cancer was 11.9%-40% in Italian study [33]. The 
commonest mechanism could be clarified this 
association; effect of high leptin level at obese 
persons, which induce pre-neoplastic epithelial cells of 
the colon [34]. 
Our results regarding post-therapeutic follow 
up and prognosis of the disease showed that obesity 
was highly statistically significant with response of 
treatment (p = 0.001, odds value > 2 and CI = 1.46-
2.72), as obese patients had progressive or stationary 
course (100% and 57.1% respectively), while normal-
weight patients had partial and complete regression 
course (60.0% and 54.5% respectively). Also, there 
was a highly statistically significant difference between 
total abdominal fat & visceral abdominal fat areas with 
good response of treatment at both sexes. This 
agreement with Jochem and Leitzmann, they found 
general obesity (BMI) and abdominal obesity had 
increased risk of colorectal cancer in both sexes [32]. 
Increased visceral fat area, not subcutaneous or total 
body fat, was established as the metabolic risk factors 
for colon cancer, those patients had 1.5 times of the 
visceral fat area compared to patients without that
 
[35]. 
Finally, this research has an important 
recommendation to add at the therapeutic strategy 
plan of colorectal cancer; reduce body weight and 
preserve it within normal to improve the response of 
the treatment.  
In conclusion, positron Emission Tomography 
(PET/CT) is the most appropriate imaging technique 
to detect any recurrence or metastases in post-
surgical& therapeutic follow up colorectal cancer 
patients with high sensitivity and specificity compared 
to computed tomography (CT). General obesity is a 
predictor risk factor for prognosis of the disease, 
although abdominal obesity (total & visceral fat) had 
an association with a therapeutic response; as the 
progressive and stationary courses of the disease 
were noticed at obese patients with high visceral and 
total abdominal fat. 
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